A Phase 1, Open-label, Single-site, Safety Study of Human Spinal Cord-derived Neural Stem Cell Transplantation for the Treatment of Chronic SCI

Trial Profile

A Phase 1, Open-label, Single-site, Safety Study of Human Spinal Cord-derived Neural Stem Cell Transplantation for the Treatment of Chronic SCI

Recruiting
Phase of Trial: Phase I

Latest Information Update: 13 Apr 2017

At a glance

  • Drugs NSI 566 (Primary)
  • Indications Spinal cord injuries
  • Focus Adverse reactions
  • Sponsors Neuralstem
  • Most Recent Events

    • 12 Apr 2017 According to a Neuralstem media release, the US FDA and the Institutional Review Board at the University of California San Diego have approved protocol amendment expanding this trial with a new cohort of four patients.
    • 07 Apr 2017 Planned number of patients changed from 4 to 8.
    • 07 Apr 2017 Planned End Date changed from 1 Mar 2016 to 1 Dec 2022.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top